GH1 and obstructive sleep apnea syndrome: In a group of patients receiving GH therapy, obstructive sleep apnea (oAHI ≥ 1.5) was noted in 23.8% of Group A and in 36.6% of Group B. OSA increased during the first three months of therapy but decreased after one year.